Major Indian pharmaceutical firm Sun Pharmaceutical Industries has undertaken a voluntary recall of 11 of its ophthalmic products within the domestic market. A company spokesperson stated that the proactive withdrawal was initiated as a matter of abundant precaution to prioritize product quality and patient safety, adding that remedial measures have been put in place.
However, the company has not yet provided specific details regarding the exact reasons behind the recall, the manufacturing locations of the affected products, or the specific remedial measures adopted. According to industry sources, the drugmaker has informed the drug regulatory authority and plans to establish a consumer helpline.
The voluntary action has drawn calls for greater transparency from public health experts. Santanu Tripathi, a senior clinical pharmacologist, noted that while the recall—implied to be due to quality or contamination concerns—is appreciated, the company needs to clearly spell out the specific reasons behind the decision.
Experts have also emphasized the need for a proactive role by state-level drug control regulators to enforce the prompt cessation of the sale and distribution of products associated with specific batch and lot numbers. Questions have been raised regarding preparations already sold and dispensed to households, clinics, and hospitals. Public health specialists suggest that information regarding the recall must be widely circulated among practicing ophthalmologists, hospital administrators, store managers, nurses, and patients to prevent further use.
Furthermore, experts have highlighted the importance of contacting patients who may have already used these products to check for adverse reactions and ensure proper investigation and compensation where a causal association is established.
Local trade checks indicate that some Mumbai-based chemists had not yet received formal information regarding the voluntary product recall at the time of reporting.
Market data from industry tracker Pharmatrac indicates that for the 12 months leading up to June 2026, the ophthalmology segment was valued at ₹4,721 crore, with eyedrops accounting for the majority share at ₹3,521 crore.
This development follows earlier international incidents involving Indian drugmakers. In November 2023, Kilitch Healthcare voluntarily recalled 27 eyedrop products from the United States following US Food and Drug Administration observations regarding unsanitary conditions. Similarly, in February 2023, Chennai-based Global Pharma Healthcare voluntarily recalled its artificial tears lubricant eyedrops distributed in the US, following investigations by the US Centres for Disease Control and Prevention into drug-resistant infections potentially linked to contaminated eyedrops.
"A voluntary product recall by a major pharmaceutical company like Sun Pharma underscores the critical importance of robust quality control and supply chain traceability in the healthcare sector. For businesses, handling such sensitive situations with complete transparency, prompt regulatory communication, and proactive consumer outreach is essential to maintaining market trust. Regulatory adherence and swift accountability protect not only consumer safety but also the long-term credibility of the enterprise." — Dr. Shishir Gupta, Founder & CEO, StartupLanes
